-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $3

Benzinga·08/13/2026 12:55:46
Listen to the news
Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and lowers the price target from $6 to $3.